GSK secures cancer approval, posts global chemo data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GSK secured approval for a cancer drug in an additional tumor type during the past week.
- GSK unveiled the first data from a global study of a next-generation chemotherapy.
- GSK had a licensed medicine highlighted in a presidential session at a major oncology conference in Madrid.
- GSK is awaiting an expected approval for a new lung-cancer drug in the coming weeks.
- GSK had been out of oncology a decade ago, placing the current approval and clinical milestones in stark contrast.
Why it matters: GSK gains a stronger oncology footing after a decade away: one cancer drug secured another tumor-type approval, a next-generation chemotherapy produced its first global-study data, and another lung-cancer approval is awaited within weeks. Together, the milestones establish activity across approval, clinical development and conference presentation.
Ask SkimNews
